Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972330 · ClinicalTrials.gov registry record · NA
Efficacy of VRx MyBiotics Oral Lozenges
A NA study of Oral Microbiome Health, sponsored by Viome.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT05972330: Completed NA study of Oral Microbiome Health, sponsored by Viome.
NCT05972330 is a NA study of Oral Microbiome Health that has completed, run by Viome. The registered enrollment target is 34 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05972330, a NA study of Oral Microbiome Health, has completed, sponsored by Viome.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will test the efficacy of Viome's VRx MyBiotics Oral Lozenges at improving the oral microbiome.
Primary Outcome
Increase in oral health score as measured by Viome's Oral Health Score.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT VRx MyBiotics Oral Lozenges
Study Locations (1)
Washington
- Viome Life Sciences - Bothell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2023-06-26 |
| Est. Completion | 2024-01-26 |
| Phase | NA |
What the finished NCT05972330 record still lists
NCT05972330 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Oral Microbiome Health appearing as the primary indexed condition, and to 1 intervention - of which VRx MyBiotics Oral Lozenges is the first listed.
NCT05972330 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05972330 about?
NCT05972330 is a clinical study titled "Efficacy of VRx MyBiotics Oral Lozenges". This study will test the efficacy of Viome's VRx MyBiotics Oral Lozenges at improving the oral microbiome.
What is the current status of trial NCT05972330?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2023-06-26. Estimated completion is 2024-01-26.
What conditions does trial NCT05972330 study?
This clinical trial studies the following conditions: Oral Microbiome Health.
What interventions are being tested in trial NCT05972330?
The interventions under investigation include: VRx MyBiotics Oral Lozenges (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05972330?
This trial is sponsored by Viome, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972330 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05972330's enrollment target sits among peer trials
34 1570th of 2000 higher than 427 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI